Table 2.

Clinical and demographic parameters in both subgroup of Covid-19 cancer patients (dead’s patients or survivors)

	Survivor patients (N = 26)	Dead patients (N = 19)	p value
Age, median	74	63.5	0.01
Male, n (%)	16 (61.5)	14 (73.68)	0.39
Cancer characteristics
Histology
Lung cancer, n (%)	8 (30.8%)	9 (47.3%)	0.20
Cancer treatment
Chemotherapy, n (%)	13 (50.0%)	6 (31.5%)	0.44
Staging
Metastatic disease, n (%)	13 (50.0%)	13 (68.4%)	0.53
Covid-19 characteristics
Covid-19 treatment
Hydroxychloroquine + azithromycin, n (%)	15 (57.7%)	3 (15.7%)	0.008
Covid-19 symptoms
Fever, n (%)	23 (88.5%)	15 (78.9%)	0.38
Cough, n (%)	23 (88.5%)	16 (84.2)	0.67
Severe infection, n (%)	12 (46.1%)	17 (89.5%)	0.003
Comorbidities
Hypertension, n (%)	11 (42.3%)	12 (63.1%)	0.16
Diabetes, n (%)
COPD, n (%)	8 (30.7%)	5 (26.3%)	0.74
CKD, n (%)	4 (15.3%)	2 (10.5%)	0.63
Cardiovascular disease, n (%)	2 (7.7%)	1 (5.3%)	0.74
Obesity, n (%)	4 (15.3%)	2 (10.5%)	0.63

COPD chronic obstructive pulmonary disease, CKD chronic kidney disease